An interventional study of Biopsies using Apollo and UroStation® and Biopsies using UroStation® (image fusion) in Prostate Cancer, sponsored by AdministrateurCIC. Completed at 1 site in France. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-18.
Sponsored by AdministrateurCIC · Not applicable and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 509 studies in Prostatic Neoplasms with a site in France — 92 open to participants now, 156 under way, 50 of them phase 3. Prostatic Neoplasms · France.
Among the 509 studies in Prostatic Neoplasms with a site in France, this one is the 372nd largest by enrollment of the 405 interventional ones that give a count, is one of 28 that started in 2014, is one of 121 with no phase, and was the 166th registered.
7,047 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →92 of the 509 studies in Prostatic Neoplasms with a site in France are open now. Recruiting first, the newest first:
AstraZeneca · Sites in France, United States, Austria and 18 more countries
Ages 18+ · Men only
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD · Sites in France, Germany, Italy and 2 more countries
Ages 18+ · Men only
Institut Cancerologie de l'Ouest · Sites in France
Ages 18+ · Men only
AstraZeneca · Sites in France, United States, Australia and 21 more countries
Ages 18+ · Men only
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
509 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 106 · Phase 3 149 · Phase 4 12
First in 1996; this study’s year is marked. 28 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 185 across the 405 interventional studies, 183 across the 99 observational. Of the 320 that completed or were terminated, 104 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
234 of 509 have an industry lead sponsor. The 10 most frequent:
AdministrateurCIC is the lead sponsor of 8 studies on the registry; none are open to participants now.
AdministrateurCIC has 2 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
38 of the studies in Prostatic Neoplasms with a site in France that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03767244Phase 3Janssen Research & Development, LLCA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 2026-12-01 |
| NCT04691804Phase 3Jiangsu HengRui Medicine Co., Ltd.A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | 2026-12-31 |
| NCT06551324Phase 3PfizerA Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). | 2027-02-28 |
| NCT06122584Phase 3ABX advanced biochemical compounds GmbHDiagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer | 2027-03 |
| NCT02531516Phase 3Aragon Pharmaceuticals, Inc.An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | 2027-03-01 |
Add all 38 to your calendar (.ics) → With an account.
Among the 509 studies in Prostatic Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study, for the first time in clinical conditions, the potential contribution, in terms of accuracy, of the motorised probe holder during prostate biopsies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The surgeon use the motorised probe handler to do the biopsy
Device: Biopsies using Apollo and UroStation® · Procedure: Biopsies using UroStation® (image fusion)
The surgeon do the biopsy as he usually do.
Procedure: Biopsies using UroStation® (image fusion)
Apollo : Motorised probe handler for prostate biopsies
Distance between virtual and effective biopsy, in the two arms
Time frame: 8 months
Success rate in locking/releasing the probe combined with success rate in performing a full exploration of the prostate
Time frame: 8 months
Probe holder positions error between virtual and effective biopsy
Time frame: 8 months
User satisfaction
* biopsies session duration * device manageability * device unwiediness * contribution of the lock of the probe * set up, cleaning * global satisfaction
Time frame: 2 hours
Safety Evaluation
* number of time the device couldn't be started * number of times the emergency button was pushed * number of time the biopsy couldn't entirely be done using the device * number of time the device protections had to be repositioned
Time frame: 2 hours
The record gives a start of May 2014, a primary completion of May 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AdministrateurCIC